Core Insights - Eli Lilly has established itself as the leader in the weight loss market with its drug Zepbound, which is currently the best-selling medicine in this niche [1][2] - The demand for anti-obesity medicines is expected to rise significantly, and despite increasing competition, Eli Lilly is likely to maintain its top position [2] Company Developments - Zepbound has demonstrated high efficacy in weight management, but competitors are developing alternative formulations such as oral or monthly options to capture market share [3] - Eli Lilly is also advancing its pipeline with eloralintide, an investigational amylin agonist, which showed a 20.1% mean decrease in body weight in a phase 2 trial compared to 0.4% in the placebo group [5] - The company is still competitive in the market, as it continues to innovate and develop new therapies [6] Financial Performance - Eli Lilly's tirzepatide has surpassed Merck's Keytruda as the world's best-selling drug, generating approximately $10 billion in sales in the third quarter, with projections suggesting it could reach nearly $62 billion by 2030 [8] - The company's shares are trading at 27 times forward earnings, which is above the healthcare average of 17.4, indicating strong financial performance [7] Future Outlook - New weight loss medications, including orforglipron and retatrutide, are expected to further boost sales, with orforglipron on track to become one of the first approved oral GLP-1 therapies [9] - Eli Lilly's ongoing clinical and regulatory advancements in the rapidly growing therapeutic area of anti-obesity medicines suggest that the stock remains reasonably valued [10]